information collection requirements contained in this document, contact Cathy Williams, 202-418-2918, or send an email to PRA@fcc.gov. SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Report and Order, IB Docket No. 18-86; FCC 19-81, adopted on August 1, 2019, and released on August 2, 2019. The full text of this document is available on the Commission's website at

is listed under that drug's name in part 556, together with any tolerances (if tolerances are established). Therefore, after removing safe concentrations from the listings, toxicological information about the drug is still reflected by the ADI. Listing of the ADI alone in part 556 provides sufficient toxicological information for the drug. We note that the safe concentrations remain available through the Freedom of Information Drug Summaries, available on the CVM website at https

www.regulations.gov website. Although listed in the index, some information is not publicly available, e.g., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in www.regulations.gov or in hard copy at Air and Radiation Docket and Information Center, EPA Docket

second for the final draft 2016 Ventura County AQMP. Combined, the public review periods lasted 43 days. The District published notices of the two public review periods on its website and in a local newspaper. The District also published notice of a public hearing to be held on February 14, 2017, for the adoption of the 2016 Ventura County AQMP. On February 14, 2017, the District held the public hearing, and, through a minute order, adopted the 2016 Ventura County AQMP and directed staff to forward

is listed under that drug's name in part 556, together with any tolerances (if tolerances are established). Therefore, after removing safe concentrations from the listings, toxicological information about the drug is still reflected by the ADI. Listing of the ADI alone in part 556 provides sufficient toxicological information for the drug. We note that the safe concentrations remain available through the Freedom of Information Drug Summaries, available on the CVM website at https

is listed under that drug's name in part 556, together with any tolerances (if tolerances are established). Therefore, after removing safe concentrations from the listings, toxicological information about the drug is still reflected by the ADI. Listing of the ADI alone in part 556 provides sufficient toxicological information for the drug. We note that the safe concentrations remain available through the Freedom of Information Drug Summaries, available on the CVM website at https

, HCC-30, (202) 366-1397, Federal Highway Administration, 1200 New Jersey Avenue SE, Washington, DC 20590. SUPPLEMENTARY INFORMATION: Electronic Access and Filing This document and all comments received may be viewed online through the Federal eRulemaking portal at http://www.regulations.gov. The website is available 24 hours each day

all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments. Table of Contents I. Background

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments.

information collection requirements contained in this document, contact Cathy Williams, 202-418-2918, or send an email to PRA@fcc.gov. SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Report and Order, IB Docket No. 18-86; FCC 19-81, adopted on August 1, 2019, and released on August 2, 2019. The full text of this document is available on the Commission's website at

received by BIS no later than February 12, 2021. ADDRESSES: See SUPPLEMENTARY INFORMATION section for information on submitting exclusion requests, objections thereto, rebuttals, and surrebuttals. You may submit comments, identified by docket number BIS-2020-0022 or RIN 0694-AH55, through the Federal eRulemaking website: http://www.regulations.gov. No

As soon as practicable, the Board will post all comments received on http://www.regulations.gov. The website http://www.regulations.gov is the Federal eRulemaking portal, and all comments posted there are available and accessible to the public. The Board requests that comments include full citations or internet links to any authority relied upon. If a comment cites a source that is not publicly available, the Board

Submit comments on the collection of information discussed in section IX.D. of this preamble both to the Coast Guard's online docket and to the Office of Information and Regulatory Affairs (OIRA) in the White House Office of Management and Budget (OMB) using their website www.reginfo.gov/​public/​do/​PRAMain. Comments sent to OIRA on the collection of information must reach OMB on or before the comment due date listed on their website

participant who does not die before the annuity starting date, the accrued benefit payable to such participant is provided in the form of a qualified joint and survivor annuity, and (ii) in the case of a vested participant who dies before the annuity starting date and who has a surviving spouse, a qualified preretirement survivor annuity is provided to the surviving spouse of such participant. (B) Plans to which

: http://www.regulations.gov. Follow the website instructions for submitting comments. Mail: Paper comments that duplicate an electronic submission are unnecessary. If you wish to submit a paper comment in lieu of electronic submission, please direct the mail/shipment to: Lauren Alder Reid, Assistant Director, Office of Policy, Executive Office for Immigration Review, 5107 Leesburg Pike, Suite 1800, Falls Church, VA 22041. To ensure proper